Not applicableNot Yet RecruitingNCT07455071
What this trial is testing
A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer
Who this might be right for
HRD-negative Epithelial Ovarian Cancer
Peking University Third Hospital 9